The purpose of the GOLDEN study is to determine if the potential new treatment, or “investigational drug” is safe and effective in slowing the progression of GA caused by AMD.
- Geographic atrophy (GA) is a late stage of age-related macular degeneration (AMD) and occurs when cells in the retina deteriorate and die, resulting in blind spots in the visual fields.
- The investigational antisense drug (or placebo) will be administered via subcutaneous injection beneath the skin in the abdomen or thigh—not into the eye. Because of this, there is the potential to treat both eyes with just one single injection.
